Ardelyx, Inc. reported a 31% year-over-year revenue increase in Q2, driven by strong demand for its drugs IBSRELA and XPHOZAH. However, near-term revenue growth is limited by payer friction, leading to a lowered revenue guidance of $350 to $370 million. Management is addressing these access challenges by expanding reimbursement teams, optimizing pharmacy networks, and increasing sales efforts to convert demand into revenue. The company trades at a discount with profitability expected by 2027, and future valuation gains depend on resolving access issues and maintaining growth momentum.
Telesat Corporation (TSAT) is transitioning from its declining geostationary satellite business to focus on its Lightspeed low-Earth-orbit (LEO) broadband project. The Lightspeed constellation has expanded to 225 satellites, targeting global commerci...
Walmart maintains a hold rating due to its premium valuation and mixed technical signals ahead of its Q2 earnings report. The company's Q1 results showed solid revenue and eCommerce growth, but cautious guidance and higher costs have dampened investo...
Jeff Booth, once skeptical of Bitcoin's decentralization and security, spent around 15,000 hours analyzing potential vulnerabilities by running a Bitcoin node and studying possible attacks. He found Bitcoin's decentralized consensus and proof-of-work...
Bitcoin and XRP are under pressure after recent declines, trading near $63,000 and below $1 respectively. Key events this week include a White House meeting with crypto leaders, potential US regulatory moves like the Digital Asset Market Clarity Act,...
Gold has risen 32% over the past year, outperforming Bitcoin, which has dropped 46%, as global government bond yields reach levels unseen since before Bitcoin's launch. Higher bond yields, especially in the US, UK, Germany, and Japan, offer investors...
